Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia.
Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with Memantine in 2014 to manage moderate and severe forms of Alzheimer's dementia. A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride once daily.
Off-label uses include the management of vascular dementia, Parkinson's Disease-associated dementia, and Lewy body dementia, amongst others.
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
- Conditions
- Alzheimer's
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-08-07
- Target Recruit Count
- 240
- Registration Number
- NCT03090516
- Locations
- 🇨🇳
Ting Wu, Nanjing, Jiangsu, China
Detecting an Early Response to Donepezil With Measures of Visual Attention
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 25
- Registration Number
- NCT03073876
- Locations
- 🇺🇸
Winthrop-University Hospital, Mineola, New York, United States
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
- Conditions
- Mild-moderate Alzheimer's Disease
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT03055741
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju-si, Jeollanam-do, Korea, Republic of
🇰🇷The Catholic University of Korea, Bucheon, ST. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Tetra Discovery Partners
- Target Recruit Count
- 38
- Registration Number
- NCT03030105
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, Austin, Texas, United States
Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Kyung Hee University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03011476
- Locations
- 🇰🇷
Kyung Hee Universtiy Hospital, Seoul, Korea, Republic of
Memory and Mental Health in Aging
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 198
- Registration Number
- NCT02988908
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT02968719
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
Donepezil Attenuate Postoperative Cognitive Dysfunction
- Conditions
- OsteoarthritisRheumatoid ArthritisFemoral Head Necrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 550
- Registration Number
- NCT02927522
- Locations
- 🇨🇳
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai, China
TAK-071 Scopolamine-Induced Cognitive Impairment Study
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18
- Registration Number
- NCT02918266
A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT02857244
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.